PD-L1 expression may be a predictive marker for the efficacy of anti-PD-1/PD-L1 monoclonal antibodies in the treatment of thymic carcinoma; however, large-scale phase III clinical studies are still needed to confirm these findings. The gene discussed is CD274; the disease is thymic carcinoma.